Evaluation of Improvement of Quality of Life in Multiple Myeloma Patients Treated With Velcade (Bortezomib) IV: Prospective, Multicenter, Observational Study
Many clinical studies for the treatment of multiple myeloma have been conducted in Korea,
but none of them have evaluated the improvement in the quality of life in patients with
multiple myeloma. Most study variables used to evaluate the quality of life of patients with
multiple myeloma are subjective and limited. This study will observe the degree of change in
the quality of life in patients with multiple myeloma before and after bortezomib
administration by using EORTC-C30 (European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire-Core30) and EQ-5D (EuroQol-5 Dimensions), validated
research instruments used to measure the quality of life in cancer patients and consequently
will provide fundamental data regarding the quality of life in patients with multiple
myeloma.. Observational Study - No investigational drug administered
Observational
Observational Model: Case-Only, Time Perspective: Prospective
The change in the quality of life as measured by EORTC QLQ-C30 and EQ-5D before and after the administration of bortezomib
Before the first, after the fourth and at the last IV cycle of bortezomib
No
Janssen Korea, Ltd. Clinical Trial
Study Director
Janssen Korea, Ltd.
Korea: Food and Drug Administration
CR012961
NCT01021592
March 2007
February 2009
Name | Location |
---|